An official website of the United States government
This repository is under review for potential modification in compliance with Administration directives.
Publication Information
Authors
Greenbaum Carla J., Serti Elisavet, Lambert Katharina, Weiner Lia J., Kanaparthi Sai, Lord Sandra, Gitelman Stephen E., Wilson Darrell M., Gaglia Jason L., Griffin Kurt J., Russell William E., Raskin Philip, Moran Antoinette, Willi Steven M., Tsalikian Eva, DiMeglio Linda A., Herold Kevan C., Moore Wayne V., Goland Robin, Harris Mark, Craig Maria E., Schatz Desmond A., Baidal David A., Rodriguez Henry, Utzschneider Kristina M., Nel Hendrik J., Soppe Carol L., Boyle Karen D., Cerosaletti Karen, Keyes-Elstein Lynette, Long S. Alice, Thomas Ranjeny, McNamara James G., Buckner Jane H., Sanda Srinath
Studies
Abstract
IL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in newly diagnosed type 1 diabetes patients.